Rectal Cancer Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewIn 2009 an estimated 40,870 new cases of rectal cancer will occur in the United States (23,580 cases in men; 17,290 cases in women). During the same year, an estimated 49,920 people will die from rectal and colon cancers.1 Although colorectal cancer is ranked as the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States, mortality from colorectal cancer has decreased during the past 30 years. This decrease may be due to earlier diagnosis through screening and better treatment modalities.The recommendations in these clinical practice guidelines are classified as category 2A except where noted, meaning that there is uniform NCCN consensus, based on lower-level evidence (including...

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225229.

  • 2

    Bonelli L, Martines H, Conio M. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988;41:513517.

    • Search Google Scholar
    • Export Citation
  • 3

    Ahsan H, Neugut AI, Garbowski GC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998;128:900905.

    • Search Google Scholar
    • Export Citation
  • 4

    Greene F, Page D, Fleming I, Fritz A. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.

  • 5

    Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295308.

  • 6

    Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416421; discussion 421.

    • Search Google Scholar
    • Export Citation
  • 7

    Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000;124:10161025.

    • Search Google Scholar
    • Export Citation
  • 8

    Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006;130:318324.

    • Search Google Scholar
    • Export Citation
  • 9

    Lai LL, Fuller CD, Kachnic LA, Thomas CR Jr. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol 2006;33(Suppl 11):S70–74.

    • Search Google Scholar
    • Export Citation
  • 10

    Nagtegaal ID, Marijnen CA, Kranenbarg EK. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350357.

    • Search Google Scholar
    • Export Citation
  • 11

    Wibe A, Rendedal PR, Svensson E. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89:327334.

    • Search Google Scholar
    • Export Citation
  • 12

    Stocchi L, Nelson H, Sargent DJ. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001;19:38953902.

    • Search Google Scholar
    • Export Citation
  • 13

    Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006;8:800807.

    • Search Google Scholar
    • Export Citation
  • 14

    Adam IJ, Mohamdee MO, Martin IG. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707711.

    • Search Google Scholar
    • Export Citation
  • 15

    Mawdsley S, Glynne-Jones R, Grainger J. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005;63:745752.

    • Search Google Scholar
    • Export Citation
  • 16

    Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26:303312.

    • Search Google Scholar
    • Export Citation
  • 17

    Sarli L, Bader G, Iusco D. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005;41:272279.

  • 18

    Newland RC, Dent OF, Lyttle MN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994;73:20762082.

    • Search Google Scholar
    • Export Citation
  • 19

    Wong SL, Hong J, Hollenbeck BK. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007;298:21492154.

    • Search Google Scholar
    • Export Citation
  • 20

    Tepper JE, O’Connell MJ, Niedzwiecki D. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19:157163.

    • Search Google Scholar
    • Export Citation
  • 21

    Pocard M, Panis Y, Malassagne B. Assessing the effectiveness of mesorectal excision in rectal cancer: prognostic value of the number of lymph nodes found in resected specimens. Dis Colon Rectum 1998;41:839845.

    • Search Google Scholar
    • Export Citation
  • 22

    Wichmann MW, Muller C, Meyer G. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002;137:206210.

    • Search Google Scholar
    • Export Citation
  • 23

    Baxter NN, Morris AM, Rothenberger DA, Teppe JE. Impact of pre-operative radiation for rectal cancer on subsequent lymph node evaluation: population based analysis. Int J Rad Oncol Biol Phys 2005;61:426431.

    • Search Google Scholar
    • Export Citation
  • 24

    Meyers MO, Hollis DR, Mayer RJ. Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: an analysis of Intergroup 0114 [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4008.

    • Search Google Scholar
    • Export Citation
  • 25

    Turner RR, Nora DT, Trocha SD, Bilchik AJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med 2003;127:673679.

    • Search Google Scholar
    • Export Citation
  • 26

    Wood TF, Nora DT, Morton DL. One hundred consecutive cases of sentinel node mapping in early colorectal carcinoma. Detection of micrometastasis. J Gastrointest Surg 2002;6:322330.

    • Search Google Scholar
    • Export Citation
  • 27

    Noura S, Yamamoto H, Miyake Y. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res 2002;8:759767.

    • Search Google Scholar
    • Export Citation
  • 28

    Yasuda K, Adachi Y, Shiraishi N. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 2001;8:300304.

    • Search Google Scholar
    • Export Citation
  • 29

    Braat AE, Oosterhuis JW, Moll FC. Sentinel node detection after preoperative short-course radiotherapy in rectal carcinoma is not reliable. Br J Surg 2005;92:15331538.

    • Search Google Scholar
    • Export Citation
  • 30

    Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008;26:15821584.

  • 31

    Amado RG, Wolf M, Peeters M. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:16261634.

    • Search Google Scholar
    • Export Citation
  • 32

    Khambata-Ford S, Garrett CR, Meropol NJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:32303237.

    • Search Google Scholar
    • Export Citation
  • 33

    De Roock W, Piessevaux H, De Schutter J. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508515.

    • Search Google Scholar
    • Export Citation
  • 34

    Punt CJ, Tol J, Rodenburg CJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract LBA 4011.

    • Search Google Scholar
    • Export Citation
  • 35

    Bokemeyer C, Bondarenko I, Makhson A. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663771.

    • Search Google Scholar
    • Export Citation
  • 36

    Tejpar S, Peeters M, Humblet Y. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4001.

    • Search Google Scholar
    • Export Citation
  • 37

    Van Cutsem E, Henning-Kohne C, Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 36014:14081417.

    • Search Google Scholar
    • Export Citation
  • 38

    Lièvre A, Bachet JB, Boige V. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374379.

    • Search Google Scholar
    • Export Citation
  • 39

    Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:17571765.

    • Search Google Scholar
    • Export Citation
  • 40

    Lievre A, Bachet JB, Boige V. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol 2008;26:374379.

    • Search Google Scholar
    • Export Citation
  • 41

    Artale S, Sartore-Bianchi A, Veronese SM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:42174219.

    • Search Google Scholar
    • Export Citation
  • 42

    Etienne-Grimaldi MC, Formento JL, Francoual M. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res 2008;14:48304835.

    • Search Google Scholar
    • Export Citation
  • 50

    Nelson H, Petrelli N, Carlin A. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583596.

  • 51

    Kapiteijn E, Marijnen CA, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638646.

    • Search Google Scholar
    • Export Citation
  • 52

    Schoellhammer HF, Gregorian AC, Sarkisyan GG, Petrie BA. How important is rigid proctosigmoidoscopy in localizing rectal cancer. Am J Surg 2008;186:904908.

    • Search Google Scholar
    • Export Citation
  • 53

    Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:10141020.

  • 54

    Weiser MR, Landmann RG, Wong WD. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum 2005;48:11691175.

  • 55

    Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136147.

  • 56

    Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am 2002;31:827839.

    • Search Google Scholar
    • Export Citation
  • 57

    Bipat S, Glas AS, Slors FJ. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology 2004;232:773783.

    • Search Google Scholar
    • Export Citation
  • 58

    Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: the current role of MRI. Eur Radiol 2007;17:379389.

  • 59

    Lahaye MJ, Engelen SM, Nelemans PJ. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 2005;26:259268.

    • Search Google Scholar
    • Export Citation
  • 60

    Beets-Tan RG, Vliegen RF, Beets GL. Magnetic resonance imaging of rectal cancer: what radiation oncologists need to know. Front Radiat Ther Oncol 2004;38:112.

    • Search Google Scholar
    • Export Citation
  • 61

    Guillem JG, Cohen AM. Current issues in colorectal cancer surgery. Semin Oncol 1999;26:505513.

  • 62

    You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 2007;245:726733.

    • Search Google Scholar
    • Export Citation
  • 63

    Landmann RG, Wong WD, Hoepfl J. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum 2007;50:15201525.

    • Search Google Scholar
    • Export Citation
  • 64

    Nash GM, Weiser MR, Guillem JG. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009;52:577582.

  • 65

    Jayne DG, Guillou, Thorpe H. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol 2007;25:30613068.

    • Search Google Scholar
    • Export Citation
  • 66

    Ng SS, Leung KL, Lee JF. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. Ann Surg Oncol 2008;15:24182425.

    • Search Google Scholar
    • Export Citation
  • 67

    Wagman LJ. Laparoscopic and open surgery for colorectal cancer: reaching equipoise? J Clin Oncol 2007;25:29962998.

  • 68

    Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 1982;69:613616.

  • 69

    Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol 2007;60:849855.

    • Search Google Scholar
    • Export Citation
  • 70

    Nagetgaal ID, van de Velde CJH, van der Worp E. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002;20:17291734.

    • Search Google Scholar
    • Export Citation
  • 71

    Marr R, Birbeck K, Garvican J. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005;242:7482.

    • Search Google Scholar
    • Export Citation
  • 72

    Pahlman L, Bohe M, Cedermark B. The Swedish rectal cancer registry. Br J Surg 2007;94:12851292.

  • 73

    den Dulk M, Putter H, Collette L. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer 2009;45:11751183.

    • Search Google Scholar
    • Export Citation
  • 74

    Steup WH, Moriya Y, van de velde CJH. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer 2002;38:911918.

    • Search Google Scholar
    • Export Citation
  • 75

    Schlag PM. Surgical sphincter preservation in rectal cancer. Oncologist 1996;1:288292.

  • 76

    Wagman R, Minsky BD, Cohen AM. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998;42:5157.

    • Search Google Scholar
    • Export Citation
  • 77

    Sauer R, Becker H, Hohenberger W. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:17311740.

  • 78

    Kachnic LA. Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol 2006;33(Suppl 11):S6469.

    • Search Google Scholar
    • Export Citation
  • 79

    Madoff RD. Chemoradiotherapy for rectal cancer—when, why, and how? N Engl J Med 2004;351:17901792.

  • 80

    Guillem JG, Diaz-Gonzolez JA, Minsky B. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008;26:368373.

    • Search Google Scholar
    • Export Citation
  • 81

    Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980987.

    • Search Google Scholar
    • Export Citation
  • 82

    Colorectal Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358:12911304.

    • Search Google Scholar
    • Export Citation
  • 83

    Peeters KCMJ, Marijnen CAM, Nagtegaal ID. The TME trial after a median follow-up of 6 years. Ann Surg 2007;246:693701.

  • 84

    Sebag-Montefiore D, Stephens RJ, Steele R. Prooperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811820.

    • Search Google Scholar
    • Export Citation
  • 85

    Gerard JP, Conroy T, Bonnetain F. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:46204625.

    • Search Google Scholar
    • Export Citation
  • 86

    Ceelen WP, van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (review). Cochrane Database Syst Rev 2009;CD006041.

    • Search Google Scholar
    • Export Citation
  • 87

    Glynne-Jones R, Sebag-Montefiore D. Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. J Clin Oncol 2006;24:46644665; author reply 4665–4666.

    • Search Google Scholar
    • Export Citation
  • 88

    Bosset JF, Calais G, Mineur L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 2005;23:56205627.

    • Search Google Scholar
    • Export Citation
  • 89

    Bosset JF, Collette L, Calais G. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:11141123.

  • 90

    Collette L, Bosset JF, den Dulk M. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the EORTC Group. J Clin Oncol 2007;25:43794386.

    • Search Google Scholar
    • Export Citation
  • 91

    Bujko K, Kepka L, Michalski W, Nowacki MP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 2006;80:412.

    • Search Google Scholar
    • Export Citation
  • 92

    Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007:CD002102.

    • Search Google Scholar
    • Export Citation
  • 93

    Peeters KC, van de Velde CJ, Leer JW. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 2005;23:61996206.

    • Search Google Scholar
    • Export Citation
  • 94

    Tepper JE, O’Connell M, Niedzwiecki D. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol 2002;20:17441750.

    • Search Google Scholar
    • Export Citation
  • 95

    Gunderson LL, Sargent DJ, Tepper JE. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:17851796.

    • Search Google Scholar
    • Export Citation
  • 96

    Johal BS, Phang P, McGahan C. Treatment patterns and outcomes of patients with pT3N0 rectal cancer in a population-based setting [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4039.

    • Search Google Scholar
    • Export Citation
  • 97

    Smalley SR, Benedetti JK, Williamson SK. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006;24:35423547.

    • Search Google Scholar
    • Export Citation
  • 98

    O’Connell MJ, Martenson JA, Wieand HS. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502507.

    • Search Google Scholar
    • Export Citation
  • 99

    Andre T, Boni C, Navarro. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol 2009;27:31093116.

    • Search Google Scholar
    • Export Citation
  • 100

    Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:26962704.

  • 101

    Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer 2005;92:18191824.

    • Search Google Scholar
    • Export Citation
  • 102

    Meyer J, Czito B, Yin FF, Willett C. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer 2007;6:348356.

    • Search Google Scholar
    • Export Citation
  • 103

    American College of Radiology. Practice Guideline for Intensity-modulated radiation therapy (IMRT), 2007; Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/imrt.aspx. Accessed July 2009

    • Search Google Scholar
    • Export Citation
  • 104

    Valenti V, Balducci M, Tororeto F. Intraoperative radiotherapy: current thinking. Eur J Surg Oncol 2002;28:180185.

  • 105

    Hahnloser D, Haddock MG, Nelson H. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am 2003;12:9931013.

    • Search Google Scholar
    • Export Citation
  • 106

    Willett CG, Czito BG, Tyler DS. Intraoperative radiation therapy. J Clin Oncol 2007;25:971977.

  • 107

    Moore HG, Gittleman AE, Minsky BD. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279286.

    • Search Google Scholar
    • Export Citation
  • 108

    Habr-Gama A, Perez RO, Proscurshim I. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008;71:11811188.

    • Search Google Scholar
    • Export Citation
  • 109

    Tulchinsky H, Shmuell E, Giger A. An interval > 7 weeks between neoadjuvant theapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:26612667.

    • Search Google Scholar
    • Export Citation
  • 110

    Tran CL, Udani S, Holt A, Arnell T. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg 2006;192:873877.

    • Search Google Scholar
    • Export Citation
  • 111

    Wolmark N, Wieand HS, Hyams DM. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92:388396.

    • Search Google Scholar
    • Export Citation
  • 112

    Benson AB III. New approaches to the adjuvant therapy of colon cancer. Oncologist 2006;11:973980.

  • 113

    Minsky BD, Guillem JG. Multidisciplinary management of resectable rectal cancer: new developments and controversies. Oncology (Williston Park) 2008;22:14301437.

    • Search Google Scholar
    • Export Citation
  • 114

    Fakih M. Treating rectal cancer: key issues reconsidered. Oncology (Williston Park) 2008;22:14441446.

  • 115

    Benson AB III. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007;13:6913s6920s.

    • Search Google Scholar
    • Export Citation
  • 116

    Sengupta S, Tjandra JJ. Local excision of rectal cancer: what is the evidence? Dis Colon Rectum 2001;44:13451361.

  • 117

    Garcia-Aguilar J, Mellgren A, Sirivongs P. Local excision of rectal cancer without adjuvant therapy: a word of caution. Ann Surg 2000;231:345351.

    • Search Google Scholar
    • Export Citation
  • 118

    Willett CG, Compton CC, Shellito PC, Efird JT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer 1994;73:27162720.

    • Search Google Scholar
    • Export Citation
  • 119

    Van Cutsem E, Nordlinger B, Adam R. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:22122221.

    • Search Google Scholar
    • Export Citation
  • 120

    Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6:202207.

    • Search Google Scholar
    • Export Citation
  • 121

    Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006;20:11611176, 1179.

  • 122

    Muratore A, Zorzi D, Bouzari H. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766770.

    • Search Google Scholar
    • Export Citation
  • 123

    Alberts SR, Horvath WL, Sternfeld WC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:92439249.

    • Search Google Scholar
    • Export Citation
  • 124

    Fong Y, Cohen AM, Fortner JG. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938946.

  • 125

    Tsai M, Su Y, Ho M. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol 2007;14:786794.

    • Search Google Scholar
    • Export Citation
  • 126

    Poultsides GA, Servais EL, Saltz LB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:33793384.

    • Search Google Scholar
    • Export Citation
  • 127

    Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis 1984;4:170179.

  • 128

    Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:14051410.

    • Search Google Scholar
    • Export Citation
  • 129

    Venook AP. The Kemeny article reviewed. Oncology 2006;20:477484.

  • 130

    Choti MA, Sitzmann JV, Tiburi MF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759766.

    • Search Google Scholar
    • Export Citation
  • 131

    Pawlik TM, Poon RT, Abdalla EK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450457; discussion 457–458.

    • Search Google Scholar
    • Export Citation
  • 132

    Charnsangavej C, Clary B, Fong Y. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:12611268.

    • Search Google Scholar
    • Export Citation
  • 133

    Vauthey JN, Zorzi D, Pawlik TM. Making unresectable hepatic colorectal metastases resectable—does it work? Semin Oncol 2005;32(Suppl 9):S118122.

    • Search Google Scholar
    • Export Citation
  • 134

    Pozzo C, Basso M, Cassano A. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933939.

    • Search Google Scholar
    • Export Citation
  • 135

    Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 2003;12:165192.

    • Search Google Scholar
    • Export Citation
  • 136

    Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13:5164.

  • 137

    Folprecht G, Grothey A, Alberts S. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:13111319.

    • Search Google Scholar
    • Export Citation
  • 138

    Reddy SK, Pawlik TM, Zorzi D. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007;14:34813491.

    • Search Google Scholar
    • Export Citation
  • 139

    Covey AM, Brown KT, Jarnagin WR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008;247:451455.

    • Search Google Scholar
    • Export Citation
  • 140

    Adam R, Miller R, Pitombo M. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am 2007;16:525536.

    • Search Google Scholar
    • Export Citation
  • 141

    Abdalla EK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg 2009;197:737739.

    • Search Google Scholar
    • Export Citation
  • 142

    Abdalla EK, Vauthey JN, Ellis LM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818825.

    • Search Google Scholar
    • Export Citation
  • 143

    Hur H, Ko YT, Min BS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197:728736.

    • Search Google Scholar
    • Export Citation
  • 144

    Gleisner AL, Choti MA, Assumpcao L. Colorectal liver metastases: recurrence and survival following hepatic resectin, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008;143:12041212.

    • Search Google Scholar
    • Export Citation
  • 145

    Reuter NP, Woodall CE, Scoggins CR. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 2009;13:486491.

    • Search Google Scholar
    • Export Citation
  • 146

    Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:20382048.

    • Search Google Scholar
    • Export Citation
  • 147

    Benoist S, Brouquet A, Penna C. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:39393945.

    • Search Google Scholar
    • Export Citation
  • 148

    Bilchik AJ, Poston G, Curley SA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005;23:90739078.

  • 149

    Adam R, Avisar E, Ariche A. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol 2001;8:347353.

    • Search Google Scholar
    • Export Citation
  • 150

    Rivoire M, De Cian F, Meeus P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:22832292.

    • Search Google Scholar
    • Export Citation
  • 151

    Vauthey JN, Pawlik TM, Ribero D. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:20652072.

    • Search Google Scholar
    • Export Citation
  • 152

    Pawlik TM, Olino K, Gleisner AL. Preoperative chemotheapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007;11:860888.

    • Search Google Scholar
    • Export Citation
  • 153

    Pawlik TM, Scoggins CR, Zorzi D. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715722.

    • Search Google Scholar
    • Export Citation
  • 154

    Elias D, Liberale G, Vernerey D. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900909.

    • Search Google Scholar
    • Export Citation
  • 155

    Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999;26:514523.

  • 156

    Adam R, Delvart V, Pascal G. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644657.

    • Search Google Scholar
    • Export Citation
  • 157

    Delaunoit T, Alberts SR, Sargent DJ. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005;16:425429.

    • Search Google Scholar
    • Export Citation
  • 158

    Nordlinger B, Sorbye H, Glimelius B. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 2008;37:10071016.

    • Search Google Scholar
    • Export Citation
  • 159

    Tan BR, Zubal B, Hawkins w. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases [abstract]. Prestented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 497.

    • Search Google Scholar
    • Export Citation
  • 160

    Folprecht G, Gruenberger T, Hartmann JT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17 2009; San Francisco, California. Abstract 296.

    • Search Google Scholar
    • Export Citation
  • 161

    Souglakos J, Androulakis N, Syrigos K. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer 2006;94:798805.

    • Search Google Scholar
    • Export Citation
  • 162

    Falcone A, Ricci S, Brunetti I. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:16701676.

    • Search Google Scholar
    • Export Citation
  • 163

    Scappaticci FA, Fehrenbacher L, Cartwright T. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173180.

    • Search Google Scholar
    • Export Citation
  • 164

    Package Insert. Bevacizumab. South San Francisco, CA, Genentech, Inc. October 2006.

  • 165

    Gruenberger B, Tamandl D, Schueller J. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:18301835.

    • Search Google Scholar
    • Export Citation
  • 166

    Reddy SK, Morse MA, Hurwitz HI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:96106.

    • Search Google Scholar
    • Export Citation
  • 167

    Lee WS, Yun SH, Chun HK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007;22:699704.

    • Search Google Scholar
    • Export Citation
  • 168

    Headrick JR, Miller DL, Nagorney DM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975979; discussion 979–980.

    • Search Google Scholar
    • Export Citation
  • 169

    Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006;20:11611176, 1179.

  • 170

    Kemeny N, Huang Y, Cohen AM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:20392048.

    • Search Google Scholar
    • Export Citation
  • 171

    Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005;352:7:734735.

  • 172

    Mulcahy MF, Lewandowski RJ, Ibrahim SM. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009;115:18491858.

    • Search Google Scholar
    • Export Citation
  • 173

    Hong K, McBride JD, Georgiades CS. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009;20:360367.

    • Search Google Scholar
    • Export Citation
  • 174

    Katz AW, Carey-Sampson M, Muhs AG. Hypofractionated stereotactic body radiation therapy (SBRT) for patients with limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007;67:793798.

    • Search Google Scholar
    • Export Citation
  • 175

    Yu T-K, Bhosale PR, Crane CH. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Rad Oncol Biol Phys 2008;71:11751180.

    • Search Google Scholar
    • Export Citation
  • 176

    Lowy AM, Rich TA, Skibber JM. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996;223:177185.

    • Search Google Scholar
    • Export Citation
  • 177

    Hoffman JP, Riley L, Carp NZ, Litwin S. Isolated locally recurrent rectal cancer: a review of incidence, presentation, and management. Semin Oncol 1993;20:506519.

    • Search Google Scholar
    • Export Citation
  • 178

    Bartlett DL, Berlin J, Lauwers GY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:12841292.

    • Search Google Scholar
    • Export Citation
  • 179

    Pelosi E, Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 2007;33:16.

    • Search Google Scholar
    • Export Citation
  • 180

    Dresen RC, Gosens MJ, Martijn H. Radical resection after IORT-containing multimodality treatment is the most important determinant of outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol 2008;15:19371947.

    • Search Google Scholar
    • Export Citation
  • 181

    Yan TD, Black D, Savady R, Sugarbaker PH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:40114019.

    • Search Google Scholar
    • Export Citation
  • 182

    Esquivel J, Sticca R, Sugarbaker P. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128133.

    • Search Google Scholar
    • Export Citation
  • 199

    Sprangers MAG, Taal BG, Aaronson NK. Quality of life in colorectal cancer: stoma vs. nonstoma patients. Dis Colon Rectum 1995;38:361369.

  • 200

    Lange MM, Mass CP, Marijnen CAM. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Cancer 2008;95:10201028.

    • Search Google Scholar
    • Export Citation
  • 201

    Lange MM, Mass CP, Marijnen CAM. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009;45:15781588.

  • 202

    DeSnoo L, Faithfull S. A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery. Eur J Cancer Care 2006;15:244251.

    • Search Google Scholar
    • Export Citation
  • 203

    Baxter NN, Habermann EB, Tepper JE. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005;294:25872593.

  • 204

    Denlinger CS, Barsevick AM. The Challenges of Colorectal Cancer Survivorship. J Natl Cancer Netw 2009;7:in press.

  • 205

    Dignam JL, Polite BN, Yothers G. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:16471654.

    • Search Google Scholar
    • Export Citation
  • 206

    Meyerhardt JA, Heseltine D, Niedzwiecki D. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006;24:35353541.

    • Search Google Scholar
    • Export Citation
  • 207

    Meyerhardt JA, Niedzwiecki D, Hollis D. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007;298:754764.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 340 226 30
PDF Downloads 147 105 14
EPUB Downloads 0 0 0